Scribe Therapeutics reported a net loss of $33.0 million for the nine months ended September 30, 2026, compared to a $12.6 million loss in the prior year period, primarily due to a significant decrease in collaboration revenue. During the quarter, the company completed its initial public offering and concurrent private placement, resulting in a cash and cash equivalents balance of $172.1 million.
Adams Street Credit Solutions Fund (ASCEND) is a business development company that reported 3,326,403.646 Class I shares outstanding as of November 12, 2026. The filing indicates the fund is an emerging growth company and a non-accelerated filer, focusing on middle-market senior loans and secured debt investments.
For the fiscal year ended September 30, 2026, RMR Group Inc. reported total revenues of $643.2 million, an 8.2% decrease from the prior year, primarily driven by lower reimbursable costs. Net income attributable to the company fell 39.2% to $10.7 million, impacted by a $19.1 million impairment loss and increased interest expenses related to new property acquisitions.
Avidbank Holdings reported a significant regulatory shift as of September 30, 2026, with none of its reciprocal deposits classified as brokered deposits due to the 21st Century ROAD to Housing Act. This compares to $475.4 million in brokered deposits at year-end 2025. The company also recorded $1.3 million in bank-owned life insurance death benefits during the first nine months of 2026.
SOLV Energy, Inc. is a non-accelerated filer reporting for the quarter ended September 30, 2026. The filing highlights risks related to project timing, labor costs, and material availability, while noting that the company has identified material weaknesses in its internal control over financial reporting.
Principal Credit Real Estate Income Trust reported net income of $6.93 million for the nine months ended September 30, 2026, a significant increase from $2.15 million in the prior year period. Total assets grew to $494.7 million, driven by investments in loans receivable, while the company continued to issue multiple classes of common shares to fund its real estate credit activities.
Ensysce Biosciences reported financial results for the third quarter of 2026, highlighting the completion of its acquisition of Cy Biopharma and the addition of lead asset CY200 for Complex Regional Pain Syndrome. The company ended the quarter with a strengthened cash position of $29.7 million and submitted a Phase 2a protocol for CY200 to the UK's MHRA.
Term
Q3 2026
“Ensysce is a fundamentally different company today than it was at the start of the year. With CY200, we now lead with a potentially first-in-class approach to CRPS, a devastating condition for which there is currently no FDA-approved therapy.”
Dr. Lynn Kirkpatrick, Chief Executive Officer
“Our priority since the acquisition has been to advance CY200 efficiently, and submitting the CYBIO 001 protocol to the MHRA in September was a significant first step.”
Innventure, Inc. reported third quarter 2026 financial results, highlighting a strategic transformation to reduce parent-level costs and focus resources on its interest in Accelsius. The company reduced its headcount from 40 to 15 since Q1 and is evaluating strategic alternatives for its AeroFlexx and Refinity businesses to address near-term liquidity needs.
Term
3 months
“Over the last few months, our management team and Board have taken decisive steps to transform Innventure into a leaner, more focused organization, concentrating our resources on the opportunities we believe offer the clearest path to driving shareholder value.”
Bill Grieco, Chief Executive Officer of Innventure
“These actions share the common objective to preserve and maximize the value of our interest in Accelsius while giving the business the necessary resources to realize its full potential.”
Bill Grieco, Chief Executive Officer of Innventure
Crown Crafts Inc. reported net income of $1.3 million for the quarter ended September 27, 2026, compared to $1.2 million in the prior year period, despite a decrease in net sales from $23.7 million to $19.0 million. For the six-month period, net income significantly improved to $3.4 million from $53,000, driven by a substantial reduction in the cost of products sold and improved gross profit margins.
Jefferson Capital, Inc. reported total revenues of $539.5 million for the nine months ended September 30, 2026, an increase from $458.5 million in the prior year period, primarily driven by higher portfolio income. Total assets grew to $2.26 billion as of September 30, 2026, while stockholders' equity increased to $518.1 million.
AnaptysBio reported net income of $3.9 million for the quarter ended September 30, 2026, compared to $15.1 million in the prior year period. The company's financial structure has shifted significantly following the spin-off of its Biopharma segment, which is now presented as discontinued operations.
Cardiff Oncology reported Q3 2026 financial results and provided a clinical update on its Phase 2 trial of onvansertib in first-line RAS-mutated mCRC, noting that median PFS has not yet been reached in the 30 mg arm. The company is preparing for a registrational Phase 3 trial expected to start in Q1 2027 and reported a cash position of $68.1 million as of September 30, 2026.
Term
Q3 2026
“We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms.”
Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology
“Building on the strength of these data, we are actively preparing for our upcoming registrational trial. There are currently no treatment options specifically approved for patients with pan RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients.”
Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology
INNOVATE Corp. reported its third quarter 2026 financial results, highlighted by a 42.8% increase in revenue to $495.5 million and a return to profitability with net income of $15.8 million. During the period, the company executed major strategic divestitures, including the sale of a controlling interest in HC2 Broadcasting and the completion of the DBM Global sale to IES Holdings shortly after quarter-end.
Term
Q3 2026
“DBM Global capped its final quarter under our ownership with exceptional performance, and we took two significant steps to reshape our portfolio through the sale of a controlling interest in HC2 Broadcasting and, shortly after quarter-end, the sale of DBM Global to IES. These transactions mark meaningful progress in our efforts to unlock the value of our assets, generate funds to help address coming debt repayment and redemption obligations, and further simplify INNOVATE's portfolio and capital structure.”
Avie Glazer, Chairman of INNOVATE
“Our focus now turns to the opportunities within our remaining portfolio, addressing liquidity and continuing to maximize value for INNOVATE shareholders. MediBeacon continues to build commercial momentum and advance its commercialization efforts in the U.S. and China, while HC2 Broadcasting is actively pursuing initiatives to unlock greater potential for its spectrum assets.”
Sanara MedTech reported net revenue of $84.4 million for the nine months ended September 30, 2026, a 12% increase over the prior year. Despite higher gross profits, the company recorded a net loss of $1.4 million for the period, primarily due to increased selling, general, and administrative expenses and interest costs.
Lulu’s Fashion Lounge reported a 20% decline in Q3 2026 net revenue to $58.6 million, driven by lower order volumes and higher return rates. Despite the revenue headwind, the company achieved a 230-basis-point gross margin expansion and a 17% reduction in inventory as it continues an assortment reset strategy.
Term
Q3 2026
“During the third quarter, we continued to advance our assortment reset and saw encouraging signs from newer product, even as the impact of historical assortment decisions remained a headwind to customer engagement and repeat purchasing behavior. While these pressures continue to weigh on revenue, we are encouraged by the improving productivity and reorder eligibility of 2026 product introductions, which reinforces our confidence that refocusing the assortment on the categories and customers where Lulus has historically differentiated itself is the right path to rebuilding customer engagement over time.”
Crystal Landsem, CEO of Lulus
“Throughout the third quarter, we maintained a disciplined approach to inventory management, expense control and working capital as we continued to drive greater efficiency across the business.”
Codexis reported Q3 2026 revenue of $19.3 million, a significant increase from $8.6 million in the prior year, driven by higher product revenue from new customer launches. The company also highlighted a new $60 million term loan facility with Trinity Capital and the successful scale-up of its ECO Synthesis Manufacturing Platform to 100-gram scale.
Term
Q3 2026
“I am pleased with our outstanding progress in 2026, through both innovation and technical achievements, that has garnered attention from leading innovators in the siRNA field.”
Alison Moore, PhD, President and Chief Executive Officer
“We have made significant progress in industrializing our technology while simultaneously increasing our revenue base, managing expenses, and improving the financial stability of our company.”
Alison Moore, PhD, President and Chief Executive Officer
Decoy Therapeutics Inc. reported a net loss of $7.59 million for the nine months ended September 30, 2026, compared to a $3.54 million loss in the prior year period, driven by a significant increase in research and development expenses. The company recognized $535,059 in grant revenue during the period and maintains a cash balance of approximately $8.17 million as of September 30, 2026.
ImmuCell Corporation reported a settlement of $2.0 million with a former contract manufacturer and a $0.1 million regulatory fee reversal following the decision to cease focus on Re-Tain®. The company is currently refitting approximately $11.8 million in idle manufacturing assets for First Defense® production and reported anti-dilutive stock options totaling 968,978 for the quarter ended September 30, 2026.
VolitionRx reported total revenues of $3.0 million for the nine months ended September 30, 2026, a significant increase from $1.3 million in the prior year, primarily driven by product sales. Despite higher revenues, the company recorded a net loss of $17.8 million for the period, impacted by $15.9 million in operating expenses and $5.0 million in other expenses including debt extinguishment costs.
SoundThinking reported a net loss of $20.2 million for the first nine months of 2026, a significant increase from the $6.6 million loss in the prior year period, driven by a decline in revenues and higher general and administrative expenses. The company also announced a pending acquisition by Transom Capital Group, LLC, which has introduced uncertainties regarding the transaction's completion and its impact on business operations.
For the nine months ended September 30, 2026, Lineage Cell Therapeutics reported total revenues of $4.2 million, a decrease from $7.9 million in the prior year, primarily due to lower collaboration revenues. The company significantly reduced its net loss compared to 2025, aided by a substantial $31.2 million non-cash gain from the change in fair value of warrant liabilities.
For the nine months ended September 30, 2026, Park Dental Partners reported revenue of $193.8 million, a 5.8% increase year-over-year, though net income decreased to $2.7 million from $5.4 million due to higher salaries and share-based compensation. The company maintained a solid liquidity position with $23.2 million in cash and cash equivalents while continuing to expand through dental practice acquisitions.
For the nine months ended September 30, 2026, Antares Strategic Credit Fund reported total investment income of $297.1 million and net investment income of $143.4 million. The fund's net asset value per share decreased to $25.02 from $25.42 at the end of 2025, primarily driven by $30.9 million in net realized and unrealized losses.
York Space Systems reported Q3 2026 revenue of $84.2 million and a significant net loss of $807.4 million, primarily driven by a $749.7 million non-cash goodwill impairment charge. The company highlighted a 30% expansion in its identified pipeline and the appointment of Brian Frantz as permanent CFO.
Term
Q3 2026
“Our identified pipeline grew more than 30 percent compared to last quarter, and we have secured the critical contract positions needed to compete for significant awards in 2027 and beyond, with IDIQ awards already converting into funded task orders.”
Dirk Wallinger, CEO of York
“Our contribution margins continue to benefit from the shift to newer programs, and we see a long-term trend toward increased profitability as we move up the value chain.”
Cardiff Oncology reported a net loss of $30.4 million for the nine months ended September 30, 2026, compared to $38.6 million in the prior year period. The company strengthened its balance sheet through the issuance of common stock and warrants, raising approximately $9.1 million in net proceeds during the third quarter of 2026.
For the nine months ended September 30, 2026, Everest Reinsurance Holdings reported net income of $797 million, an increase from $541 million in the prior year period, despite a decrease in earned premiums. The company's total stockholder's equity remained stable at $8.5 billion, as net income was largely offset by $793 million in other comprehensive losses primarily driven by unrealized depreciation of securities.
Scribe Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $174.2 million following its successful upsized IPO. The company is advancing its Phase 1 clinical trial for STX-1150, an epigenetic silencing therapy for LDL-C lowering, with initial data expected in the first half of 2027.
“This is a period of continued execution for Scribe, marked by the successful completion of our IPO and expansion of our collaboration with Sanofi to include the epigenetic silencing technology. Together, these milestones strengthen our foundation as we work to translate the potential of our technologies into meaningful medicines for patients.”
Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics
ProMIS Neurosciences reported a significant increase in cash to $44.1 million as of September 30, 2026, compared to $6.1 million at the end of 2025, primarily driven by financing activities that increased additional paid-in capital. The company's accumulated deficit grew to $158.5 million, reflecting ongoing research and development costs, while total shareholders' equity improved to a positive $41.8 million.
Crown Crafts reported second quarter fiscal 2027 results, with net income increasing to $1.3 million despite a decline in net sales to $19.0 million. The company achieved a significant gross margin expansion to 32.0%, driven by profitability initiatives and tariff refunds, and declared a quarterly dividend of $0.03 per share.
Term
Q2 2027
“We continue to execute well on our profitability initiatives with meaningful improvement this quarter in our gross profit, marketing and administrative expenses, and year-to-date operating cash flow.”
Olivia Elliott, President and Chief Executive Officer
“Our stronger profitability reflects our continued initiatives around efficiency and profitability, and our talented team is simultaneously focused on the development of additional higher-margin products and sales channels to grow both sales and profitability in the quarters ahead.”
Olivia Elliott, President and Chief Executive Officer
4D Molecular Therapeutics is a clinical-stage genetic medicine company reporting 56,379,402 shares of common stock outstanding as of November 9, 2026. The company continues to incur significant net losses and requires substantial additional capital to fund the development of its lead AAV product candidates, including 4D-150 and 4D-175.